1A concise analysis of innovative anticancer drugs approved by FDA in 1999-2014Alita, WU Zhi-ang1081-10902The lesson of failure is more reliable than successful experience in developing new drugsLI Feng-jie, LI Lian-da, LI Yi-kui1091-10923Inspiration of India "Delhi" mode to realize the goals of national essential drug systemWANG Dan-ping1093-10954Systematic introduction about clinical research management of HMS DF/HCC: entire process management of clinical researchCAO Ye1096-10995Development and suggestion of biosimilar monoclonal antibodyWANG You-fu, YUAN Xi-bin, ZHANG Juan1100-11046Key technical points in clinical trial design of the new drugs of traditional Chinese medicine for the treatment of strokeLIU Bing-lin1105-1107,11277Influences on intestinal absorption of (-)-Syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside in a rat model of in situ single-pass perfusionHUANG Hai-ying, GUO Yan-li, HE Yuan-song, WU Min-xuan, LI Jian, YU Ding-rong, SHI Jin-li1108-11128Preparation and accelerated release test of ropivacaine mesilate micropheresZHAO Xi-qing, LI Zhi-ping, ZHAO Shi-qing, LIU Yan, XIAO Ruo-lei, MEI Xing-guo1113-11189Target identification of bioactive small moleculesWANG Dong-yao, CHEN Xiao-fei, CAO Yan, ZHU Zhen-yu, ZHANG Jun-ping, CHAI Yi-feng1119-112310Advances in application of articular cavity microdialysis in pharmacokinetics and pharmacodynamicsSHAN Lian-ju, DING Han-ying, WANG Rui, LI Yong-ji1124-112711A new cancer treatment strategy: combined drug therapy to simultaneously kill tumor cells and cancer stem cellsWANG Mei-ping, GONG Zhi-rong, ZHANG He, ZHONG Yan-qiang, LU Ying1128-1133,114412The role of pharmacokinetics in Beagle dogs for preclinical evaluation of extended-release formulationsYUAN Lin-wen, YANG Jin1134-114013Reporting of informed consent and ethics committee approval in clinical trials of antihypertensive drugs1141-114414Strategies of the initiation and design of paediatric drug trialsLU Yao-wen, HE Yan-ling, CHENG Guo-hua, SUN Ming-jie, WANG Ting1145-114915Intentional attitude analysis for adverse drug event reporting of principal investigators in clinical trialsZENG Ling-feng, LIU Jun, PAN Jian-ke, WANG Lu, WANG Ke-zhu, ZENG Xing, WANG Qi1150-1154,115916A randomized study comparing the efficacy and safety of Shumian capsules and Jieyuanshen capsules in the treatment of insomniaLIANG Ying, WANG Wei-dong, ZHANG Hong-yan, WANG Xing-chen, GU Wan-li, ZHAO Shi-ke, WEI Ming1155-115917Relationship between EPIYA motif polymorphisms of Helicobacter pylori and gastroduodenal diseases in ChongqingLIN Zhen, TIAN Zhi-ying, ZHU Li-li, TIAN Ling, ZHENG Jian, YANG Zhi-bang1160-1165,117018Synthesis of impurities of the novel cholesterol-lowering drug candidate WS070117ZHANG Wen-xuan, LI Bo, WU Hong-na, WANG Dong-mei, WU Song1166-117019Construction and evaluation of HER2-targeted PAMAM dendrimer drug delivery systemMA Peng-kai, ZHANG Xue-mei, LI Jin-ming, NI Ling, WANG Zheng, ZHANG Feng-pu, SUN Kao-xiang1171-1177,118620A general method for the determination of residual protein in fermented antibioticsWANG Yan, YAO Shang-chen, CHANG Yan, CHONG Xiao-meng, MA Yue, HU Chang-qin1178-1186 